1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Anthrax - Pipeline Review, H1 2016

Anthrax - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 166 pages

Anthrax - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Anthrax - Pipeline Review, H1 2016’, provides an overview of the Anthrax pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anthrax, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Anthrax
- The report reviews pipeline therapeutics for Anthrax by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anthrax therapeutics and enlists all their major and minor projects
- The report assesses Anthrax therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anthrax

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anthrax
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anthrax pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Anthrax - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Anthrax Overview 8
Therapeutics Development 9
Pipeline Products for Anthrax - Overview 9
Pipeline Products for Anthrax - Comparative Analysis 10
Anthrax - Therapeutics under Development by Companies 11
Anthrax - Therapeutics under Investigation by Universities/Institutes 13
Anthrax - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Anthrax - Products under Development by Companies 17
Anthrax - Products under Investigation by Universities/Institutes 20
Anthrax - Companies Involved in Therapeutics Development 21
Aduro BioTech, Inc. 21
Altimmune, Inc. 22
Aphios Corporation 23
Aradigm Corporation 24
AtralCipan 25
Cellceutix Corporation 26
ContraFect Corporation 27
Dynavax Technologies Corporation 28
Elusys Therapeutics, Inc. 29
Emergent BioSolutions Inc. 30
GlaxoSmithKline Plc 31
Green Cross Corporation 32
Grifols, S.A. 33
Hawaii Biotech, Inc. 34
iBio, Inc. 35
Merck and Co., Inc. 36
Microbiotix, Inc. 37
NanoBio Corporation 38
ONI BioPharma Inc. 39
PaxVax, Inc. 40
Pfenex Inc. 41
PharmAthene, Inc. 42
Protein Potential, LLC 43
ProThera Biologics, LLC. 44
Soligenix, Inc. 45
Syntiron LLC 46
Tetraphase Pharmaceuticals Inc. 47
United Therapeutics Corporation 48
VLP Biotech, Inc. 49
Anthrax - Therapeutics Assessment 50
Assessment by Monotherapy Products 50
Assessment by Combination Products 51
Assessment by Target 52
Assessment by Mechanism of Action 54
Assessment by Route of Administration 56
Assessment by Molecule Type 58
Drug Profiles 60
anthrax (virus like particles) vaccine - Drug Profile 60
anthrax + plague vaccine - Drug Profile 61
anthrax vaccine - Drug Profile 62
anthrax vaccine - Drug Profile 63
anthrax vaccine - Drug Profile 64
anthrax vaccine - Drug Profile 65
anthrax vaccine - Drug Profile 66
anthrax vaccine - Drug Profile 67
anthrax vaccine - Drug Profile 69
anthrax vaccine 2 - Drug Profile 70
anthrax vaccine next generation - Drug Profile 72
ARD-3100 - Drug Profile 73
AV-7909 - Drug Profile 75
CF-306 - Drug Profile 76
CF-307 - Drug Profile 77
CF-308 - Drug Profile 78
ciprofloxacin hydrochloride - Drug Profile 79
DPX-Anthrax - Drug Profile 80
DV-230 - Drug Profile 81
Epimerox - Drug Profile 82
GC-1109 - Drug Profile 83
GREANX - Drug Profile 84
Human Antibody Based Vaccines - Drug Profile 85
KKL-35 - Drug Profile 87
Marinus - Drug Profile 88
Monoclonal Antibody for Respiratory Anthrax - Drug Profile 89
Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax - Drug Profile 90
obiltoxaximab - Drug Profile 91
OG-253 - Drug Profile 93
PBI-220 - Drug Profile 95
Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile 97
PMX-0196 - Drug Profile 98
PMX-0243 - Drug Profile 99
PMX-225 - Drug Profile 100
PMX-231 - Drug Profile 101
PreviThrax - Drug Profile 102
Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile 104
Px-563L - Drug Profile 105
raxibacumab - Drug Profile 106
RC-100b - Drug Profile 107
RiVax + SGX-204 - Drug Profile 108
Second Generation Px-563L - Drug Profile 109
SGX-204 - Drug Profile 110
Small Molecule to Inhibit DNA Helicase for Infectious Diseases - Drug Profile 111
Small Molecule to Inhibit Enoyl-Reductase for Anthrax and Tularaemia - Drug Profile 112
Small Molecules for Anthrax - Drug Profile 113
Small Molecules for Bacterial Infections - Drug Profile 114
Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax - Drug Profile 115
Small Molecules to Inhibit Lethal Factor for Anthrax - Drug Profile 116
Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile 118
Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile 119
solithromycin - Drug Profile 120
TP-271 - Drug Profile 123
Anthrax - Recent Pipeline Updates 125
Anthrax - Dormant Projects 149
Anthrax - Discontinued Products 153
Anthrax - Product Development Milestones 154
Featured News and Press Releases 154
Appendix 161
Methodology 161
Coverage 161
Secondary Research 161
Primary Research 161
Expert Panel Validation 161
Contact Us 161
Disclaimer 162

List of Tables
Number of Products under Development for Anthrax, H1 2016 13
Number of Products under Development for Anthrax - Comparative Analysis, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Number of Products under Development by Companies, H1 2016 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2016 17
Comparative Analysis by Late Stage Development, H1 2016 18
Comparative Analysis by Clinical Stage Development, H1 2016 19
Comparative Analysis by Early Stage Development, H1 2016 20
Products under Development by Companies, H1 2016 21
Products under Development by Companies, H1 2016 (Contd..1) 22
Products under Development by Companies, H1 2016 (Contd..2) 23
Products under Investigation by Universities/Institutes, H1 2016 24
Anthrax - Pipeline by Aduro BioTech, Inc., H1 2016 25
Anthrax - Pipeline by Altimmune, Inc., H1 2016 26
Anthrax - Pipeline by Aphios Corporation, H1 2016 27
Anthrax - Pipeline by Aradigm Corporation, H1 2016 28
Anthrax - Pipeline by AtralCipan, H1 2016 29
Anthrax - Pipeline by Cellceutix Corporation, H1 2016 30
Anthrax - Pipeline by ContraFect Corporation, H1 2016 31
Anthrax - Pipeline by Dynavax Technologies Corporation, H1 2016 32
Anthrax - Pipeline by Elusys Therapeutics, Inc., H1 2016 33
Anthrax - Pipeline by Emergent BioSolutions Inc., H1 2016 34
Anthrax - Pipeline by GlaxoSmithKline Plc, H1 2016 35
Anthrax - Pipeline by Green Cross Corporation, H1 2016 36
Anthrax - Pipeline by Grifols, S.A., H1 2016 37
Anthrax - Pipeline by Hawaii Biotech, Inc., H1 2016 38
Anthrax - Pipeline by iBio, Inc., H1 2016 39
Anthrax - Pipeline by Merck and Co., Inc., H1 2016 40
Anthrax - Pipeline by Microbiotix, Inc., H1 2016 41
Anthrax - Pipeline by NanoBio Corporation, H1 2016 42
Anthrax - Pipeline by ONI BioPharma Inc., H1 2016 43
Anthrax - Pipeline by PaxVax, Inc., H1 2016 44
Anthrax - Pipeline by Pfenex Inc., H1 2016 45
Anthrax - Pipeline by PharmAthene, Inc., H1 2016 46
Anthrax - Pipeline by Protein Potential, LLC, H1 2016 47
Anthrax - Pipeline by ProThera Biologics, LLC., H1 2016 48
Anthrax - Pipeline by Soligenix, Inc., H1 2016 49
Anthrax - Pipeline by Syntiron LLC, H1 2016 50
Anthrax - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2016 51
Anthrax - Pipeline by United Therapeutics Corporation, H1 2016 52
Anthrax - Pipeline by VLP Biotech, Inc., H1 2016 53
Assessment by Monotherapy Products, H1 2016 54
Assessment by Combination Products, H1 2016 55
Number of Products by Stage and Target, H1 2016 57
Number of Products by Stage and Mechanism of Action, H1 2016 59
Number of Products by Stage and Route of Administration, H1 2016 61
Number of Products by Stage and Molecule Type, H1 2016 63
Anthrax Therapeutics - Recent Pipeline Updates, H1 2016 129
Anthrax - Dormant Projects, H1 2016 153
Anthrax - Dormant Projects (Contd..1), H1 2016 154
Anthrax - Dormant Projects (Contd..2), H1 2016 155
Anthrax - Dormant Projects (Contd..3), H1 2016 156
Anthrax - Discontinued Products, H1 2016 157

List of Figures
Number of Products under Development for Anthrax, H1 2016 13
Number of Products under Development for Anthrax - Comparative Analysis, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Number of Products under Investigation by Universities/Institutes, H1 2016 17
Comparative Analysis by Clinical Stage Development, H1 2016 19
Comparative Analysis by Early Stage Products, H1 2016 20
Assessment by Monotherapy Products, H1 2016 54
Number of Products by Top 10 Targets, H1 2016 56
Number of Products by Stage and Top 10 Targets, H1 2016 56
Number of Products by Top 10 Mechanism of Actions, H1 2016 58
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 58
Number of Products by Routes of Administration, H1 2016 60
Number of Products by Stage and Routes of Administration, H1 2016 60
Number of Products by Top 10 Molecule Types, H1 2016 62
Number of Products by Stage and Molecule Types, H1 2016 62

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016 Summary Global Markets ...

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) ...

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘N-Formyl ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.